Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson’s Disease

BACKGROUND: Intraputamenal glial cell line-derived neurotrophic factor (GDNF), administered every 4 weeks to patients with moderately advanced Parkinson’s disease, did not show significant clinical improvements against placebo at 40 weeks, although it significantly increased [(18)F]DOPA uptake throu...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Parkinsons Dis
Κύριοι συγγραφείς: Whone, Alan L., Boca, Mihaela, Luz, Matthias, Woolley, Max, Mooney, Lucy, Dharia, Sonali, Broadfoot, Jack, Cronin, David, Schroers, Christian, Barua, Neil U., Longpre, Lara, Barclay, C. Lynn, Boiko, Chris, Johnson, Greg A., Fibiger, H. Christian, Harrison, Rob, Lewis, Owen, Pritchard, Gemma, Howell, Mike, Irving, Charlie, Johnson, David, Kinch, Suk, Marshall, Christopher, Lawrence, Andrew D., Blinder, Stephan, Sossi, Vesna, Stoessl, A. Jon, Skinner, Paul, Mohr, Erich, Gill, Steven S.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: IOS Press 2019
Θέματα:
Research Report
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6597995/
https://ncbi.nlm.nih.gov/pubmed/30829619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JPD-191576
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια